RECRUITING

Xeomin® and Gait Related Mobility After Stroke

Conditions

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The aim of the present pilot study is to evaluate the association between change in gait related mobility in ambulatory male and female adult hemiparetic patients before and 4-6-weeks after Xeomin® injection into the upper limb, using two standardized tests of physical function in outpatient rehabilitation that are widely used; the 10-meter walk test and the timed 'up and go' test (TUG).

Official Title

Upper Extremity Injection of Xeomin® and Changes in Gait Related Mobility in Adults After Stroke

Quick Facts

Study Start:2021-10-19
Study Completion:2026-04
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04908423

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 79 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Diagnosis of hemiparesis and spasticity secondary to stroke with upper and lower limb spasticity and unilateral motor and/or sensory deficit
  2. * No prior surgery to the lower limb
  3. * Able to walk at least 10 meters without physical assistance from another person and without an assistive device
  4. * Toe- ground clearance during swing phase without assistive device or orthoses
  5. * No treatment with botulinum toxin within the past 4 months
  1. * Passive range of motion at either the ankle, knee, or elbow joint less than 30 degrees
  2. * Participants with uncorrected hearing impairment
  3. * Weight bearing restrictions due to concurrent orthopedic injuries that would make ambulating with or without an assistive device unsafe
  4. * Speech language expression deficit (e.g., aphasia)
  5. * Absence of proprioception upon neurologic examination
  6. * Presence of fixed contractures in the upper or lower extremities not correctable to neutral
  7. * Other confounding neurological diagnoses or active acute illness (cancer, Parkinson's disease, multiple sclerosis)

Contacts and Locations

Study Contact

Mark A Hirsch, PhD
CONTACT
704-355-7673
Mark.Hirsch@atriumhealth.org
Christine Patino, RN, BSN
CONTACT
704-355-9368
Christine.Patino@atriumhealth.org

Principal Investigator

Mark A Hirsch, PhD
PRINCIPAL_INVESTIGATOR
Wake Forest University Health Sciences

Study Locations (Sites)

Carolinas Rehabilitation
Charlotte, North Carolina, 28203
United States

Collaborators and Investigators

Sponsor: Wake Forest University Health Sciences

  • Mark A Hirsch, PhD, PRINCIPAL_INVESTIGATOR, Wake Forest University Health Sciences

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-10-19
Study Completion Date2026-04

Study Record Updates

Study Start Date2021-10-19
Study Completion Date2026-04

Terms related to this study

Additional Relevant MeSH Terms

  • Stroke